The U.S. Food and Drug Administration has approved Lipfendra (Merck) as a once-daily oral medication for lowering LDL (“bad”) cholesterol. Multiple outlets report the drug represents the first oral treatment of its kind, using a newer drug class: PCSK9 inhibitors. The medication is designed to help the liver remove more LDL from the bloodstream.
Sources say Lipfendra is intended for people with hypercholesterolemia, including patients with hereditary forms of the condition that cause elevated LDL levels. Several reports frame it as an alternative to existing cholesterol-lowering approaches, particularly for patients who previously relied on injections associated with PCSK9 inhibitors. One outlet also notes that Lipfendra can be used alongside statins or as an alternative to statins.
Overall, the coverage describes FDA approval as providing a new treatment option for patients with difficult-to-manage LDL levels, including those who need additional lowering beyond what statins can achieve or who cannot tolerate statins. The reports do not detail pricing or long-term comparative outcomes in the provided excerpts.
